Workflow
万邦德医药控股集团股份有限公司关于股票交易异常波动的公告

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (July 14, 2025, July 15, 2025, and July 16, 2025) [1] - The company conducted an internal review and confirmed that there were no undisclosed significant matters affecting the stock price, and the operational situation remains normal [2][3] - The company has not identified any recent media reports that could have significantly impacted the stock trading price [2] Group 2 - The company confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange regulations [3] - The company announced a half-year performance forecast on July 15, 2025, with no need for corrections [4] - The company’s controlling shareholder intends to transfer 60 million shares, representing 9.8089% of the total share capital, which is subject to compliance review and transfer procedures [4] Group 3 - The company emphasizes the importance of rational investment and awareness of market risks, particularly given the recent volatility in stock prices [4][5]